In a report issued on June 15, Jason Kolbert from Dawson James maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $19.00. The company's shares closed last Friday at $8.47, close to its 52-week low of $7.13. According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -3.6% and a 34.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Citius Pharmaceuticals. Currently, the analyst consensus on Anavex Life Sciences is a Strong Buy with an average price target of $34.00.
https://www.tipranks.com/news/blurbs/dawson-james-thinks-anavex-life-sciences-stock-is-going-to-recover-4?utm_source=advfn.com&utm_medium=referral
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Anavex Life Sciences Charts.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Anavex Life Sciences Charts.